About EMIG 2 2019-07-01T12:02:45+00:00

Who We Are

EMIG is a multi-stakeholder network and trade industry association that represents the interests of the full span of life sciences companies in the UK. Our industry Members, range from new business start-ups focused on R&D, through to well-established companies delivering a wide range of essential medicines to patients.

Our Members

EMIG Members supply 50% of branded medicines, by volume, to the NHS.

EMIG is the sole representative body of 90% of its Members.


EMIG has over 270 Member Companies and organisations – including Associate Members drawn from academia, patient organisations, learned societies and companies providing essential support services to the Life Sciences ecosystem. Collectively we represent the breadth of the health and medicines ecosystem, from research, clinical development and manufacturing, through to patient charities, research policy organisations and academic institutions. This means EMIG has become a platform for greater knowledge and ideas exchange.

EMIG is a member of the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE).

EMIG Members List


Academy of Medical Sciences
Accord Healthcare
Action Duchenne
Action on Hearing Loss
Addex Therapeutics
Aegerion Pharma
Aguettant UK Ltd
Akcea Therapeutics
Alan Pharmaceuticals
Alexion Pharmaceuticals
Alison Campbell Associates
Alkaptonuria Society
Allergan Ltd
Alliance Pharma plc
Altacor Pharma Ltd
Alveo Solutions
Amicus Therapeutics
Amryt Pharma
Amyloidosis Research Consortium
Andrew Carr Associates
APCER Pharma Europe Ltd
ApoPharma Inc
Applied Driving Techniques
Aquila Biolabs
Ashfield Healthcare
Aspire Pharma
Association of Medical Research Charities
Atlantic Healthcare
Avitus Group
Axess Ltd
Axis Healthcare Consulting


Bellicum Pharmaceuticals
BGP Products Ltd (Mylan)
Bial Pharma
BioCryst Pharmaceuticals
Biotest UK Ltd
Biotherapy Services
Birmingham Health Partners
Bloom Health Ltd
Blue Chip Healthcare
Bob Hackett Training Consultancy
Bowater Holographics
Brabant Pharma
Brandcast Health
Brancaster Pharma
Britannia Pharmaceuticals
British Liver Trust
Business France


C3 Collaborating for Health
C&C Group
C&D Data
Cambridge Enterprise
Cambridge Healthcare
Cambridge Rare Disease Network
Campbell Charles Associates (2000) Ltd
Cancer Research UK
Celdra Ltd
Cello Health Public Affairs
CG Pharma
Chantrey Vellacott
Charlwood Pharma
Cheemia Ltd
Chiesi Pharmaceuticals
Clarity Pharma Ltd
Conseptua Training & Consulting
Costello Medical
Consilient Health
Corbett Keeling
Crawford Pharma
Creo Pharma
CSL Behring
Curium Pharma
Custom Healthcare
Cystic Fibrosis Trust


Daiichi Sankyo
Daniel and Daisy Novel Therapeutics Ltd
Davies Consulting
Dee Pharmaceuticals Ltd
Derma UK
Dermal Laboratories Ltd
Desitin Pharma
Dexcel Pharma
Diabetes Professional Care
Dierks & Company
Discovery Pharmaceuticals
Draper & Dash
Dr Falk Pharma UK Ltd
DRG – Decision Resources Group
Dr Reddy’s


Equa Pharma Ltd
ESMS Global – Emergency Scientific & Medical Services
European Association for Logistics and Transportation in Healthcare
European Confederation of Pharmaceutical Entrepreneurs
EUSA Pharma
Eventum Partners


Ferring Pharmaceuticals Ltd
Fight for Sight
Fish Pharma Recruitment
Flynn Pharma
Four Public Affairs
FTI Consulting
Funding Neuro


Galderma (UK) Ltd
Gedeon Richter
Genetic Alliance
Genetic Disorders UK
Genomics England
Genzyme Therapeutics Ltd
Gilead Sciences Int ltd
Grey Bear Consultancy
Grifols UK Ltd
Guerbet Laboratories
GW Pharmaceuticals


Havas M&C
Haworth Consulting
Healthcare at Home
Healthcare Business Managers Group
Helm Pharmaceuticals
Henry Schein UK Holdings Ltd
HFA Healthcare Products Ltd
Horizon Pharma
HRA Pharma Ltd


Idea Pharma
Imperial College London
IMS Health
Intercept Pharmaceuticals
International Health Partners
Intrapharm Laboratories
IQ Pharma


Jazz Pharmaceuticals
Jenson R+


Kidney Research UK
King’s Health Partners
Kowa Research Europe Ltd
Kyowa Kirin


Leadiant Biosciences
Leicester School of Pharmacy, De Montfort University
Leukaemia CARE
LFB Biopharmaceuticals
Lightning-API Ltd
Logixx Pharma Ltd
Lucane Pharma SA


Making Pharmaceuticals
Map BioPharma
Martindale Pharma
Masters Global Pharma
MaimoniDex RA Ltd/MaimoniDex (UK) Ltd
MedDay Pharmaceuticals
Medical Need Europe
Medical Research Council Technology
Merck Group
Merz Pharma Ltd
Metabolic Support UK
Mibe Pharma Ltd
Moorfields Pharmaceuticals
Morningside Healthcare
MORPh Consultancy Ltd
MPA Business services
Muscular Dystrophy Campaign
Myeloma UK


Nanogenics Ltd 
National Clinical Homecare Association

NHS Confederation
National Services for Health Improvement
National Voices
Neubourg Pharma UK
Network Pharma
NHS Alliance
Nordic Pharma
North 51
NSF Pharma Biotech


Open Health
Orion Pharma
Orphan Insight Ltd


ParaPharm Development
Patients Direct
Penlan Healthcare Ltd
Pharma Solutions
Pharmaceutical Marketing Society
Pharmiweb Solutions
pi2 Health
Pierre Fabre
Pinsent Masons
Polycystic Kidney Disease Charity
Plymouth University
Portola Pharmaceuticals
Precision Medicine Catapult
Premier Research
Present Value Ltd
Primius Lab Ltd


Quantum Pharma
Queen Mary University of London


Rapidscan Pharma Solutions
Raptor Pharmaceuticals Europe
Rare Disease UK
Rarer Cancers Foundation
Real Regulatory
Ridge Pharma
Roboleo & Co
Rocket Science Consultancy
Royal Society of Biology


Santhera Pharmaceuticals
Sciensus Ltd
Seek Pharma
Servier Laboratories Ltd
Sigma-Tau Pharmaceuticals
Sinclair IS Pharma
Soar Beyond
Spark Therapeutics
Spirit Healthcare
STD Pharmaceuticals
Star Medical
Stirling Anglian Pharmaceuticals
Stratagem+ Ltd
Structural Genomics Consortium, Oxford University
Surepharm Services Ltd
Swedish Orphan Biovitrum Ltd
Syneos Health


Tanner Pharma
Targeted Solutions Ltd
Technology4Events Ltd
Teijin Pharma
The Alkaptonuria Society
The Healthcare Partnership
The Institute of Cancer Research
The M.E. Trust
Thea Pharmaceuticals
The Medical Research Network
The Royal Osteoporosis Society
The Urology Company Ltd
Thornton & Ross Pharmaceuticals
Tillotts Pharma (UK) Ltd
TLP Delivers
TRAC Services
Typharm Ltd


UCL Business
UCL Partners
UK Innovation Forum
United Therapeutics
Universities UK
University of Bristol
University of Leicester
University of Manchester
University of Southampton, Research & Innovation Services
University of Wolverhampton


V Pharma
Veale Wasbrough Vizards
Vidant Pharma
Vifor Pharma


Wave Data Ltd
WEP Clinical
Whately-Smith Ltd
Williams Medical Supplies
Wilmington Healthcare
Wyndham Hynds Ltd





Zebra26 Ltd

What We Do

EMIG enables members to network and meet like-minded professionals who experience the same industry challenges

David Bloomfield

All our Special Interest Group meets three times a year in central London and any member is entitled to join.

Darren Spevick

EMIG represents its Members on the issues directly affecting their businesses.

Leslie Galloway

How we work

EMIG Steering Group
  • The Steering Group oversees the operation of the organisation, its priorities and work programme, and is led by our Chairman, Leslie Galloway. We are unique among life sciences trade associations in that we have a patient organisation representative on the Group.
  • Members of the EMIG Steering Group include our Chairman, Leslie Galloway, Vice Chairman, Abid Karim, Legal Advisor Paul Ranson, Eric Low OBE of the Amyloidosis Research Consortium, and 12 heads of Member Companies.
  • Our policy is ‘One Member – One Vote’. This means our work programme can be developed and approved by the full breadth of our Membership, with full transparency.









EMIG Projects & Collaborations

  • EMIG is committed to collaborative working with academia, charities, patient groups and research-focused bodies to encourage scientific research and innovation in the UK. Better Research for Better Outcomes is an initiative joining up stakeholders from these communities to lead a work programme that seeks to develop a UK value framework for better research.
  • Through EMIG’s Medical Directors Forum, we enable all types of Member organisations to work for collaborative advantage, to encourage the sharing of pre-competitive data and best practices, and to ensure that knowledge, innovation and enterprise can be effectively curated within our part of the life sciences sector in the UK.
  • EMIG works alongside our trade association colleagues in life sciences on shared issues.
Special Interest Groups
We have a number of Special Interest Groups (SIGs) to reflect the differing interests and needs of the myriad roles that make a successful biopharmaceutical company. SIGs meet quarterly and inform EMIG positions on a wide range of issues, from regulation and research, to pricing and orphan diseases.
Each Group has a Chair and the Group determines the content of each meeting agenda.
All our SIGs meet quarterly, mostly in central London, and any Member is entitled to join. Policy proposals made by the SIGs are reviewed by the EMIG Steering Group, and ratified by the Membership, often at our Quarterly Meetings throughout the year.
See how our Special Interest Groups can benefit you:
EMIG has the following Special Interest Groups:
Business Development

The EMIG Business Development group is a networking meeting for those members focussed on building their business by M&A, licensing, partnering and novel in market strategies.

The group meets quarterly at the Manor, Weston on the Green, Oxfordshire. Every meeting starts with a networking lunch followed by an afternoon of interesting content which might typically include:

  • A member company showcasing their business and strategy
  • Case histories of deals completed
  • Contemporary topics affecting the marketplace
  • Professional advice & services from member companies

Many delegates choose to stay for the networking dinner and overnight.

The group was established in 2010 and has become a firm fixture on the UK business development calendar.






The EMIG Digital Health Group is a networking meeting for those members focused on understanding the latest developments in digital health and going “beyond the pill”.  

The group meets 3 times a year, typically in London. Every meeting starts with a networking coffee followed by a few hours of interesting content which might typically include presentations by:

  • members on what they are doing in digital health
  • digital health companies
  • other relevant stakeholders e.g., NHS Digital, digitalhealth.london, MHRA etc

The group was established in 2016 to meet the need within this new environment. 


The finance group brings together colleagues from across the finance community of member companies on a quarterly basis to learn, debate and help shape the critical topics and issues affecting the industry from a finance perspective.

The finance group is focussed on offering members an opportunity to…

  • network and meet like-minded professionals who experience the same industry challenges
  • gain knowledge and learn, with presentations and talks that are focussed on our needs
  • have a sounding board for practical issues and give support to others
  • learn from others experiences and explore different approaches
  • debate the important topics

The EMIG HR Group meets four times per year in London and provides a great opportunity for HR Professionals to come together for networking and the exchange and sharing of information and new ideas.

We regularly feature external speakers and the members have the opportunity to agree future topics to be explored at future meetings. We also offer members the opportunity to:

  • learn from others experiences and explore different approaches
  • gain knowledge and learn, with presentations and talks that are focussed on our needs
  • network and meet like-minded professionals who experience the same industry challenges
  • debate the important topics
  • have a sounding board for practical issues and give support to others

With a seemingly endless flow of legislative initiatives from Brussels and the need for the UK Government to implement such changes, it has never been more important to keep up with these developments – current issues include pricing and reimbursement transparency, data protection, medical devices approval and safety, biosimilars and rare diseases. This is in addition to other changes that impact on companies more widely such as competition law, EU employment developments, bribery and corruption, tax and patents and other intellectual property.

So that EMIG members can keep up to date with changes that most affect their business Pinsent Masons LLP and Alexander Natz, Secretary-General of EUCOPE have agreed to establish and run a quarterly EU and Legal Issues Special Interest Group. The aim will be to review recent and forthcoming changes and discuss in depth issues where Governmentconsultation is ongoing or where urgent action may be necessary.

Meetings will be held at Pinsent Masons’ offices in the City. Further details including the agenda will be sent out by way of a reminder nearer the time.

Market Access

The Market Access Group aims to:

  • Reduce the hurdles to uptake in the UK and enable innovative products to reach patients in a timely manner

  • Identify cost-effective solutions to market access challenges

  • Work with government and officials to communicate solutions to market access challenges

  • Understand the impact on the varied range of EMIG member companies (biotechs to mature companies) of gaining market access in the UK

Medical Directors’ Forum

The EMIG Medical Directors’ Forum aims:

  • To promote a scientific and medical research policy and operating environment that supports optimally the growth and sustainability of small to medium-sized pharmaceutical companies.

  • To identify and access new opportunities for technology development with academia and the NHS.

  • To build an innovative open platform for knowledge exchange and collaboration between diverse life sciences organisations

Northern Ireland

We provide a platform for engagement with the NHS and other stakeholders in Northern Ireland and enable networking across Member companies with shared learning.

We provide political updates and insights at our Group meetings.


The EMIG Regulatory group hold regular information sharing and networking meetings for those members working in Regulatory Affairs, related disciplines or those with an interest in understanding more about current challenges impacting the industry.

The group meets at least three time a year in London.  Each meeting focuses on current hot topics and take the form of presentations and/or group discussions. External experts and Regulatory Authority personnel are often invited as appropriate.  Examples of recent topics include:

  • GMP/GDP – led by MHRA inspectorate
  • Source Transfer Masterclass – group discussion around current challenges
  • Patient Information

Events are a valuable networking opportunity, with time allocated at the start of each session for informal networking.

In addition, the EMIG Regulatory group takes the lead on two key MHRA meetings for our membership:

  • Cross trade meeting
  • Bi-lateral meeting

The group was established in 2008 and is developing along with EMIG member requirements to ensure it has value for all.


Scotland Group focuses on issues including:

  • Co-operation with the Scottish Lifesciences Association

  • Engagement with SMC and how we can reduce the cost of SMC submissions for SMEs

  • SMC position on uptake – clinical standards

  • CEL 17 and the question of how it needs to be implemented in Health Boards

  • Planning post-election engagement with the new political encumbents


Wales Group was established to:

  • Provide a voice for members in Wales

  • Build relations with the All Wales Medicines Strategy Group and with key stakeholders in the Welsh Assembly

  • Engage with the Bio Industry in Wales.

EMIG’s mission

“We work closely with government, regulators, HTA bodies, academia, medical research organisations and the NHS to advance patient access to the most effective and innovative medicines; to promote the UK as an attractive environment for research and investment; and to enhance our Members’ ability to operate effectively.”










Our Values

In pursuing our mission we strive to be:

  • Patient-centred

  • Accountable

  • Results focused

  • Collaborative

  • Innovative

  • Evidence-based

  • Open